Blue Oak Pharmaceuticals

Blue Oak Pharmaceuticals was a private CNS-focused biotech developing first-in-class and best-in-class small-molecule therapies for serious brain disorders. The company combined custom-designed chemotypes with systems neurobiology assays, behavioral profiling, medicinal chemistry, informatics, and brain imaging to identify and advance novel neuropsychiatric drug candidates. Its stated focus included schizophrenia, bipolar disorder, treatment-resistant depression, and geriatric psychosis. Available sources indicate the company operated from the Boston-area biotech ecosystem and raised early-stage financing, but more recent company-status sources suggest it is no longer active and is out of business.